Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea.
10.3346/jkms.2018.33.e290
- Author:
Woon YOON
1
;
Seung Hyun SHON
;
Youjin HONG
;
Yeon Ho JOO
;
Jung Sun LEE
Author Information
1. Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. js_lee@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Bipolar Disorder;
Antidepressants;
Prescription Patterns
- MeSH:
Antidepressive Agents;
Antipsychotic Agents;
Anxiety Disorders;
Bipolar Disorder*;
Bupropion;
Citalopram;
Consensus;
Female;
Fluoxetine;
Humans;
Korea*;
Prescriptions*;
Prevalence
- From:Journal of Korean Medical Science
2018;33(46):e290-
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: The role of antidepressants (ADs) in bipolar disorder is long-standing controversial issue in psychiatry. Many clinicians have used ADs as a treatment for bipolar depression, and the selection of therapeutic agents is very diverse and inconsistent. This study aimed to examine recent AD prescription patterns for patients with bipolar disorder in Korea, using the nationwide, population-based data. METHODS: This study utilized the Korean nationwide, whole population-based registry data of the year 2010, 2011, and 2013. All prescription data of the ADs, antipsychotics, and mood stabilizers of the sampled patients diagnosed with bipolar disorder (n = 2,022 [in 2010]; 2,038 [in 2011]; 2,626 [in 2013]) were analyzed for each year. RESULTS: Annual prescription rate of ADs was 27.3%–33.6% in bipolar disorder, which was gradually increasing over the 3-year period. The combination pattern of ADs and antipsychotic drugs tended to increase over 3 years. The proportion of females and the prevalence of comorbid anxiety disorder were significantly higher in AD user group in all three years. Among individual ADs, escitalopram was prescribed most frequently, and fluoxetine and bupropion were prescribed to the next many patients. The mean duration of bipolar depressive episodes was 135.90–152.53 days, of which ADs were prescribed for 115.60–121.98 days. CONCLUSION: Our results show prescription rate of ADs in bipolar disorder was maintained at substantial level and increased in recent 3 years. More empirical data and evidence are needed to establish practical treatment consensuses.
